components of new drug application and biologics license application (5of15) redi– may 29-30, 2019
Published 4 years ago • 12K plays • Length 36:55
Download video MP4
Download video MP3
Similar videos
-
38:21
nda and bla application review process (6of15) redi annual conference – may 29-30, 2019
-
36:06
what can cder do for you? (3of15) redi annual conference – may 29-30, 2019
-
58:43
so, your nda was approved – now what?! post-approval responsibilities and obligations- redi 2020
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
0:15
us fda drug product application types
-
10:03
new drug application | regulatory affair
-
19:58
cder industry assistance resources (13of15) redi – may 29-30, 2019
-
41:30
meetings: pre-submission and special programs (4of15) redi annual conference – may 29-30, 2019
-
10:31
ora aligned for the future (1of15) redi – may 29-30, 2019
-
35:51
orange book exclusivity: part ii - pediatric, orphan, and gain
-
18:10
sbia program overview - redi 2020
-
42:43
regulatory highlights for biosimilars and interchangeables (9of15) redi – may 29-30, 2019
-
7:35:04
redi annual conference 2024: cder (drugs) innovation in medical product development (day 1 of 2)
-
1:08
registration open: regulatory education for industry (redi) 2021
-
34:20
a medical officer’s approach to nda/bla review (8of15) redi annual conference – may 29-30, 2019
-
14:31
biosimilars and interchangeables - regulatory highlights (27of33) quality – oct. 16-17, 2019
-
1:10:48
cmc - nda requirements and common pitfalls of blas (14of15) redi – may 29-30, 2019
-
51:53
mid-cycle assessment and post-complete response letter meetings (6of28) gdf – apr. 3-4, 2019
Clip.africa.com - Privacy-policy